Level D· Scientific groundwork from lab and animal studiesLaboratory StudyEurope PMCOpen access

AB239. Icariside II enhances endothelial nitric oxide synthase expression by suppressing miR-155 in diabetic-like human cavernous endothelial cells

Laboratory Study on Systemic / IV, published in Transl Androl Urol (2016) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Transl Androl Urol (2016)
Reported sample size
—
Source database
Europe PMC
PMCID
PMC4842673

Abstract (original English)

Background To investigate the role of Icariside II (ICA II) on endothelial nitric oxide synthase (eNOS) expression regulated by miR-155, the human cavernous endothelial cells (HCECs) were exposed to a diabetic-like environment and treated with ICA II. Methods HCECs were treated with 200 µg/mL BSA as the Normal Control group (NC), with 200 µg/mL AGE-BSA plus 250 mg/dL glucose as the diabetes mellitus (DM) group, or with an addition of ICA II in DM group as the treatment group (DM+ICA II). Bioinformatics were first used to predict miRNAs targeting eNOS gene and then potential candidates including miR-155, miR-543, miR-31, miR-429, miR-200b were further verified by real-time PCR in a diabetic-like condition. Expressions levels of miRNAs, eNOS and the receptor for advanced glycation end products (RAGE) were performed by Real-time PCR; Protein expression levels of eNOS and RAGE were analyzed by western blot; nitric oxide (NO) content was detected by DAF-FM DA probe and NaNO2 standard curve methods. Results The expression of miR-155 in DM group is significantly higher than that that in the normal control (NC) group, whereas this phenomenon was effectively reversed by ICA II treatment. Furthermore, the miR-155 targeting gene eNOS and its consequent NO product were significantly reduced in DM group, while these changes were also recovered after ICA II treatment. Conclusions In this stu

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research